Hydrocodone, Urine
Hydrocodone is a semisynthetic opioid agonist derived from codeine. Hydrocodone is the most commonly prescribed drug in the US and is frequently co-formulated with non-opioid analgesics such as acetaminophen or ibuprofen. Hydrocodone is also co-formulated with drugs such as chlorpheniramine or homatropine in cough syrups. The typical route of administration is oral (tablets, solution, etc). The principle therapeutic metabolite is hydromorphone, which is pharmacologically active and contributes to the analgesic effect of the drug. Because CYP2D6 is a primary metabolic pathway for production of hydomorphone, rapid metabolizers may produce excess hydromorphone while poor metabolizers may not respond well to hydrocodone. In most patients, the metabolites norhydrocodone and hydrocodol (dihydrocodeine stereoisomer) appear at higher concentrations than hydromorphone. Hydrocodone does not form glucuronide conjugates but hydromorphone is eliminated largely as a conjugate. The half-life of immediate release hydrocodone is 3.4-8.8 hours and the half-life of hydromorphone is 3-9 hours.
Approximately 26% of the parent drug (hydrocodone) is excreted into the urine within 72 hours of a dose. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.
Common side effects: sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention, and anxiety. Hydrocodone can also contribute to the following effects: euphoria, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory depression and collapse, seizure, coma, and possible death.
Hydrocodone and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.
- Adherence monitoring
- Drug abuse evaluation
- Toxicity/Overdose assessment
Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Frozen: 30 days
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
- Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
- Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.